Alzheimer Disease & Dementia

What dementia treatment makes an interesting appearance in classical literature?

Cognitive disorders are varied and complicated, and require a close eye...

A study on a new Alzheimer disease vaccine lacks concrete numbers.

Cognitive impairment is not always associated with dementia. For this reason, a full comprehensive history is an integral component of any assessment. Take the quiz to learn more.

What consequences will big data and artificial intelligence have on brain health and economics?

A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.

A new treatment for hallucinations and delusions in individuals with Alzheimer disease may be on the horizon.

New developments in Alzheimer disease treatment and research.

The Lumipulse® G β-Amyloid Ratio in vitro diagnostic test was filed for 510(k) premarket clearance.

A new study associates a gene that facilitates neuron communication in the nervous system with memory loss.

Telehealth poses challenges for patients, clinicians, families, and caregivers.

Patients with chronic inflammatory diseases, especially rheumatoid arthritis, are at 800% increased risk for developing Alzheimer disease compared to the general population. A new treatment is in the works to combat this inflammation.

Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.

Often misdiagnosed as other psychiatric disorders, FTD is the third most common type of dementia and the second most common among patients 65 years or younger. How to spot the signs.

Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.

According to some estimates, nearly 2.3 million people in the US suffer from dementia-related psychosis. The Gerontological Society of America’s diagnostic and treatment considerations help shed light on this complicated condition.

How do you determine whether pain is present and its severity as well as how it responds to treatment in patients who are cognitively impaired? Some answers to these questions.

How can clinicians determine the presence of pain in cognitively impaired patients? And how do you know the medication is working if your patient can’t tell you?

How can psychiatrists help caregivers deal with behavioral disturbances at home, without the possibility of an in-person doctor’s appointment? In this video, Marc E. Agronin, MD, offers tips for helping patients with Alzheimer disease and other dementias.

During this time, many individuals with Alzheimer disease are homebound with their caregivers. Here's how clinicians can help caregivers deal with common dilemmas under stay-at-home orders.

BPSD is associated with worse outcomes for patients with dementia. Management is not standardized, but protocols generally involve the treatment of underlying symptoms followed by the use of nonpharmacological management techniques and evidence-based pharmacotherapy for refractory BPSD.

At present there are no treatments to stop or delay underlying disease progression. Current prevalent therapies help to mask the symptoms, but they do not solve underlying causes. A fundamental premise for effective treatment is to make a diagnosis of Alzheimer disease at the earliest stage.

In this video, Marc E. Agronin, MD, discusses several factors that may play a role in agitation. One would be underlying medical causes. It could be an acute disease state impairing brain function. And the list goes on.

A Conversation in Critical Psychiatry with Peter J. Whitehouse, MD, PhD.

Recommendations for the use of antipsychotics for the management of behavioral and psychological symptoms of dementia.